# A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

> **NCT02291055** · PHASE1,PHASE2 · TERMINATED · sponsor: **Advaxis, Inc.** · enrollment: 75 (actual)

## Conditions studied

- Cervical Cancer
- Cancer
- Head and Neck Cancer

## Interventions

- **DRUG:** ADXS11-001
- **DRUG:** MEDI4736

## Key facts

- **NCT ID:** NCT02291055
- **Lead sponsor:** Advaxis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04
- **Primary completion:** 2019-07-09
- **Final completion:** 2020-11-20
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02291055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02291055, "A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT02291055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*